Myelodysplastic Syndrome — Trials

Myelodysplastic Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 336
Recruiting: 196
Ph III recruiting: 9
Growth YoY: +2.1%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 33.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (307)

clinicaltrialsPublishedShowing 1–50 of 125 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03839771	A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML)	active not recruiting	Phase 3	968	Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER	15	Sep 22, 2026	clinicaltrials
NCT00843882	Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia	active not recruiting	Phase 3	247